Bharat Biotech's homegrown COVID-19 vaccine has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Indian company said on Wednesday.
The interim analysis was based on 43 recorded cases of COVID-19 in the trial of 25,800 participants, conducted in partnership with the Indian government's medical research body.
Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6%, the company said.
India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness.
India's vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca.
Earlier this week, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN.
Trump says he does not need China's help to end Iran war
Britain to bring 10 people to UK for precautionary isolation after hantavirus outbreak
US war in Iran has cost $29 billion so far, Pentagon says
At Temple of Heaven summit, Trump and Xi will seek a good harvest
Peace deal hopes fade after Trump rejects Iran proposal
Protests erupt after key college entrance test cancelled in India
UK's Starmer defies calls to quit, says he is getting on with governing
New Israeli law sets military tribunal for those linked to October 7 attack
